Intellia and Regeneron Present Updated Interim Data of NTLA-2001 in P-I Study for the Treatment of Transthyretin Amyloidosis at EASL 2022
Shots:
- The P-I study evaluates NTLA-2001 which showed sustained durability of serum TTR reduction with follow-up @12mos. in 0.1/0.3mg/kg & 6mos. in 0.7/1.0mg/kg
- Pk modeling & simulation indicated that 80mg fixed-dose provides similar exposure to 1.0mg/kg. NTLA-2001 at 1.0mg/kg resulted in 93% mean & 98% maximum serum TTR reduction by 28 days in 6 patients while 3 patients reached 9mos. of follow-up with no loss in TTR reduction
- In 0.7 & 0.3mg/kg dose cohort, 86% & 89% mean serum TTR reduction @28days & 12mos. & remained durable @6mos. In 0.1 & 0.3mg/kg, patients reached 12mos. of follow-up with durable response. The companies are expected the results from the cardiomyopathy in H2’22 with an expected enrollment completion in ATTRv-PN & ATTR-CM in 2022
Ref: GlobalNewswire | Image: Intellia
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
